Review
Version 1
Preserved in Portico This version is not peer-reviewed
COVID-19 Vaccines: Where Do We Stand at the End of 2023?
Version 1
: Received: 4 January 2024 / Approved: 5 January 2024 / Online: 5 January 2024 (10:09:54 CET)
A peer-reviewed article of this Preprint also exists.
Lundstrom, K. COVID-19 Vaccines: Where Did We Stand at the End of 2023? Viruses 2024, 16, 203. Lundstrom, K. COVID-19 Vaccines: Where Did We Stand at the End of 2023? Viruses 2024, 16, 203.
Abstract
Vaccine development against SARS-CoV-2 has been highly successful in slowing down the COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole viruses, protein subunits and peptides, viral vectors, and nucleic acids have been developed in parallel. For all types of COVID-19 vaccines, good safety and efficacy have been obtained in both preclinical animal studies and in clinical trials in humans. Moreover, emergency use authorization has been granted for all types of COVID-19 vaccines. Although high safety has been demonstrated, rare cases of severe adverse events have been detected after global mass vaccinations. Emerging SARS-CoV-2 variants possessing enhanced infectivity have affected vaccine protection efficacy requiring re-design and re-engineering of novel COVID-19 vaccine candidates. Furthermore, insight into preparedness against emerging SARS-CoV-2 variants and other future viral infections is given.
Keywords
inactivated and live whole virus vaccines; protein and peptide vaccines; viral vector vaccines; DNA vaccines; RNA vaccines
Subject
Biology and Life Sciences, Virology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment